Navigation Links
Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference
Date:11/18/2009

der a federal contract worth up to $44.4 million. This contract, which is funding work at Peregrine and at several collaborating institutions, was awarded based on positive data from earlier studies in animals infected with VHF that was funded by a previous grant from NIAID.

Bavituximab, which is Peregrine's most advanced PS-targeting antibody, is currently being studied in a clinical trial for the treatment of patients co-infected with HCV and HIV. Phase I studies in HCV patients showed that bavituximab was well tolerated and it exhibited encouraging signs of anti-viral activity. Bavituximab is also being tested in Phase II clinical trials for the treatment of advanced breast cancer and non-small cell lung cancer.

Peregrine's collaborators at UT Southwestern Medical Center, the University of Utah at Logan and the University of Texas Medical Branch at Galveston also contributed to this research. The poster, "Phosphatidylserine-Targeting Antibodies as Therapeutic Agents for Viral Hemorrhagic Fever Infections," A. Brideau-Andersen, M. Soares, P. Thorpe, B. Gowen, J. Julander, A. Grant, C.J. Peters, W. Chu, S. Hirst, M. Wakabayashi, K. Schlunegger, B. Freimark, was presented on November 17, 2009 at the 2009 Chemical and Biological Defense Science and Technology Conference.

About Phosphatidylserine (PS)-Targeting Antiviral Agents

PS, a lipid molecule normally found only on the inside of cell membranes, becomes exposed on the outside of the membranes of viruses and virally infected cells. A rapidly growing body of published scientific research confirms that exposed PS is directly involved in the pathogenesis of many serious infectious diseases. Exposed PS enables viruses to evade immune recognition and dampens the body's normal responses to infection. By masking the exposed PS, PS-targeting antibodies are believed to block these effects, allowing the body to develop a robust immune response to the pathogen. P
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
2. Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
3. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
4. Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
5. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
6. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
7. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
8. Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
9. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
10. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
11. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... YORK , Oct. 22, 2014 New ... in the in vitro diagnostic (IVD) test industry, especially ... Information. The healthcare market researcher listed more than 25 testing ... could be the future of IVD products. Kalorama details the ... The Worldwide Market for In Vitro Diagnostic Tests ...
(Date:10/22/2014)... The North American crystal oscillator market report defines ... and forecast of revenue. This market was valued at ... $623.6 million by 2018, at a CAGR of 3.3% ... of the North American crystal oscillator market report, to ... also provides a glimpse of the segmentation of the ...
(Date:10/22/2014)... San Diego, CA (PRWEB) October 22, 2014 ... laboratory balances from Sartorius, A & D Weighing, ... Sartorius CPA Semi-Micro Balance . The Sartorius ... looking for an affordable high-quality, precise, and user-friendly ... in manufacturing of laboratory equipment, their laboratory balances ...
(Date:10/22/2014)...   Synthetic Biologics, Inc. (NYSE MKT: SYN), ... infections and diseases, announced today that the U.S. Patent ... for a composition of matter patent application that covers ... SYN-004. This is Synthetic Biologics, first allowed patent application ... to the Company,s extensive C. difficile patent ...
Breaking Biology Technology:Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today ... and year-end 2008 financial results on Wednesday, February 4, ... be followed by a conference call at 5:00 p.m. ... telephone and webcast. During the conference call, the company ...
... a,subsidiary of KV Pharmaceutical (NYSE: KVa/KVb), is issuing, ... 26, 2009, a nationwide,voluntary recall of the products ... a wholesale or a retail level as a ... conditions that did not,sufficiently comply with current Good ...
... Japan,s first second-generation drug-eluting stentNATICK, Mass., Jan. 28 ... ) announced today that it has received approval ... Welfare (MHLW) to market its TAXUS(R) Liberte(R) Paclitaxel-Eluting ... launch the product as soon as reimbursement approval ...
Cached Biology Technology:Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast 2Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast 3ETHEX Corporation Issues Nationwide Voluntary Recall of Products 2ETHEX Corporation Issues Nationwide Voluntary Recall of Products 3ETHEX Corporation Issues Nationwide Voluntary Recall of Products 4ETHEX Corporation Issues Nationwide Voluntary Recall of Products 5ETHEX Corporation Issues Nationwide Voluntary Recall of Products 6Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System 2Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System 3
(Date:10/25/2014)... Research and Markets  has announced the addition of ... to their offering. Biometrics is a ... of their physical or behavioral patterns. It involves the ... fingerprints, face recognition, DNA, palm print, hand geometry, and ... and speech pattern/voice recognition. The data ...
(Date:10/22/2014)... -- Leading identity analyst firm Acuity Market Intelligence forecasts that ... will have a chip-based National eID card, including near-complete ... Asia , with its vast population, is ... 60% of all National eID cards issued between 2014 ... National eID Industry Report: 2014 Edition" — ...
(Date:10/18/2014)... 19th October 2014 Psychological stress and stress-related psychiatric ... aging-related diseases, but the molecular mechanisms underlying ... may contribute to the development of targeted ... for these devastating diseases. This work is ... congress in Berlin., Now an international group ...
Breaking Biology News(10 mins):Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 2Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 3Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Researchers find why depression and aging linked to increased disease risk 2
... the atmosphere and moving into marine systems, the world,s ... To address the growing concern for acidifying marine systems, ... under the Ocean Acidification theme of its Climate Research ... Office of Polar Programs, Directorate for Geosciences, and Directorate ...
... October 13, 2010) Before Alzheimer,s patients experience memory loss, ... A new study in mouse models by researchers ... mitochondria -- the powerhouses of the cell -- are one ... appeared in the online Early Edition of PNAS, also found ...
... North American comb jellyfish can sneak up on its ... successful predator. Researchers, including one from the University of ... jellyfish makes itself hydrodynamically ,invisible,. The North American ... known to consume vast quantities of zooplankton. A few ...
Cached Biology News:NSF awards grants to study effects of ocean acidification 2NSF awards grants to study effects of ocean acidification 3NSF awards grants to study effects of ocean acidification 4NSF awards grants to study effects of ocean acidification 5NSF awards grants to study effects of ocean acidification 6NSF awards grants to study effects of ocean acidification 7NSF awards grants to study effects of ocean acidification 8NSF awards grants to study effects of ocean acidification 9NSF awards grants to study effects of ocean acidification 10Early role of mitochondria in AD may help explain limitations to current beta amyloid hypothesis 2Voracious comb jellyfish 'invisible' to prey 2